21-Sept-2026 19:52:26
SYMBIOTEC PHARMALAB DELIVERS STEADY PERFORMANCE FOR Q1FY27
• Consolidated revenues stood at ₹218.2 Cr vs ₹203.2 Cr (YOY). • Consolidated EBIDTA was ₹45.2 Cr vs ₹58.0 Cr (YOY). • Consolidated PAT stood at ₹14.1 Cr vs ₹2…
Latest market headlines for SYMBIOTEC on Terminal.
21-Sept-2026 19:52:26
• Consolidated revenues stood at ₹218.2 Cr vs ₹203.2 Cr (YOY). • Consolidated EBIDTA was ₹45.2 Cr vs ₹58.0 Cr (YOY). • Consolidated PAT stood at ₹14.1 Cr vs ₹2…
21-Sept-2026 18:47:12
• The board of directors approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. • The trading window for dea…